Medicina
Departamento
Hacettepe University
Ankara, TurquíaPublicaciones en colaboración con investigadores/as de Hacettepe University (50)
2024
-
Clinical nutrition in primary care: ESPEN position paper
Clinical Nutrition
-
Consensus position statement on advancing the standardised reporting of infection events in immunocompromised patients
The Lancet Infectious Diseases, Vol. 24, Núm. 1, pp. e59-e68
-
Examining the environmental risk factors of progressive-onset and relapsing-onset multiple sclerosis: recruitment challenges, potential bias, and statistical strategies
Journal of neurology, Vol. 271, Núm. 1, pp. 472-485
-
Invasive Fungal Diseases in Adult Patients in Intensive Care Unit (FUNDICU): 2024 consensus definitions from ESGCIP, EFISG, ESICM, ECMM, MSGERC, ISAC, and ISHAM
Intensive Care Medicine
-
Pembrolizumab plus concurrent chemoradiotherapy versus placebo plus concurrent chemoradiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (KEYNOTE-412): a randomised, double-blind, phase 3 trial
The Lancet Oncology
2023
-
Characterization and outcomes of 414 patients with primary SS who developed haematological malignancies
Rheumatology (United Kingdom), Vol. 62, Núm. 1, pp. 243-255
-
Early non-disabling relapses are important predictors of disability accumulation in people with relapsing-remitting multiple sclerosis
Multiple sclerosis (Houndmills, Basingstoke, England), Vol. 29, Núm. 7, pp. 875-883
-
Gaps in clinical research in frontotemporal dementia: A call for diversity and disparities–focused research
Alzheimer's and Dementia, Vol. 19, Núm. 12, pp. 5817-5836
-
Predictors of treatment switching in the Big Multiple Sclerosis Data Network
Frontiers in Neurology, Vol. 14
-
Risk factors for infections caused by carbapenem-resistant Enterobacterales: an international matched case-control-control study (EURECA)
eClinicalMedicine, Vol. 57
-
The risk of secondary progressive multiple sclerosis is geographically determined but modifiable
Brain : a journal of neurology, Vol. 146, Núm. 11, pp. 4633-4644
2022
-
Effect of Combination Antibiotic Empirical Therapy on Mortality in Neutropenic Cancer Patients with Pseudomonas aeruginosa Pneumonia
Microorganisms, Vol. 10, Núm. 4
-
Phase II study of afatinib plus pembrolizumab in patients with squamous cell carcinoma of the lung following progression during or after first-line chemotherapy (LUX-Lung-IO)
Lung Cancer, Vol. 166, pp. 107-113
-
Pseudomonas aeruginosa Bloodstream Infections in Patients with Cancer: Differences between Patients with Hematological Malignancies and Solid Tumors
Pathogens, Vol. 11, Núm. 10
-
Risk of infection in patients with hematological malignancies receiving CAR T-cell therapy: systematic review and meta-analysis
Expert Review of Anti-Infective Therapy, Vol. 20, Núm. 11, pp. 1455-1476
2021
-
Co-infections and superinfections complicating COVID-19 in cancer patients: A multicentre, international study
Journal of Infection, Vol. 83, Núm. 3, pp. 306-313
-
Global guideline for the diagnosis and management of rare yeast infections: an initiative of the ECMM in cooperation with ISHAM and ASM
The Lancet Infectious Diseases, Vol. 21, Núm. 12, pp. e375-e386
-
Impact of the inclusion of an aminoglycoside to the initial empirical antibiotic therapy for gram-negative bloodstream infections in hematological neutropenic patients: a propensity-matched cohort study (AMINOLACTAM study)
Antimicrobial Agents and Chemotherapy, Vol. 65, Núm. 8
-
Invasive Aspergillosis Due to Aspergillus Section Usti: A Multicenter Retrospective Study
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, Vol. 72, Núm. 8, pp. 1379-1385
-
Nutrition education in medical schools (NEMS) project: Joining ESPEN and university point of view
Clinical Nutrition, Vol. 40, Núm. 5, pp. 2754-2761